← Back to Screener
Innate Pharma S.A. ADS (IPHA)
Price$1.59
Favorite Metrics
Price vs S&P 500 (26W)-37.00%
Price vs S&P 500 (4W)11.55%
Market Capitalization$152.04M
All Metrics
Book Value / Share (Quarterly)$0.07
P/TBV (Annual)18.20x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-61.69%
Cash Flow / Share (Quarterly)$-0.66
Price vs S&P 500 (YTD)-22.09%
Gross Margin (TTM)0.81%
Net Profit Margin (TTM)-1103.12%
EPS (TTM)$-0.64
10-Day Avg Trading Volume0.54M
EPS Excl Extra (TTM)$-0.64
Revenue Growth (5Y)-45.15%
EPS (Annual)$-0.65
ROI (Annual)-124.21%
Gross Margin (Annual)1.29%
Net Profit Margin (5Y Avg)-544.85%
Cash / Share (Quarterly)$0.43
Revenue Growth QoQ (YoY)-35.62%
ROA (Last FY)-78.41%
Revenue Growth TTM (YoY)-64.68%
EBITD / Share (TTM)$-0.68
ROE (5Y Avg)-154.41%
Operating Margin (TTM)-1211.48%
Cash Flow / Share (Annual)$-0.66
P/B Ratio25.09x
P/B Ratio (Quarterly)27.27x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)27.72x
Net Interest Coverage (TTM)0.39x
ROA (TTM)-63.19%
EV / EBITDA (TTM)12.44x
EPS Incl Extra (Annual)$-0.65
Current Ratio (Annual)1.27x
Quick Ratio (Quarterly)1.14x
3-Month Avg Trading Volume0.21M
52-Week Price Return-26.14%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.12
P/S Ratio (Annual)46.31x
Asset Turnover (Annual)0.04x
52-Week High$2.10
Operating Margin (5Y Avg)-576.31%
EPS Excl Extra (Annual)$-0.65
CapEx CAGR (5Y)-58.48%
Tangible BV CAGR (5Y)-40.70%
26-Week Price Return-28.26%
Quick Ratio (Annual)1.14x
13-Week Price Return-13.68%
Total Debt / Equity (Annual)3.51x
Current Ratio (Quarterly)1.27x
Enterprise Value$145.544
Revenue / Share Growth (5Y)-46.53%
Asset Turnover (TTM)0.06x
Book Value / Share Growth (5Y)-47.95%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-1764.51%
Cash / Share (Annual)$0.43
3-Month Return Std Dev58.91%
Gross Margin (5Y Avg)67.81%
Net Income / Employee (TTM)$-0
ROE (Last FY)-560.01%
Net Interest Coverage (Annual)5.98x
EPS Basic Excl Extra (Annual)$-0.65
P/FCF (TTM)46.87x
Receivables Turnover (TTM)8.56x
Total Debt / Equity (Quarterly)5.25x
EPS Incl Extra (TTM)$-0.64
Receivables Turnover (Annual)5.35x
ROI (TTM)-127.92%
P/S Ratio (TTM)28.95x
Pretax Margin (5Y Avg)-532.69%
Revenue / Share (Annual)$0.04
Tangible BV / Share (Annual)$0.12
Forward P/E33.00x
Price vs S&P 500 (52W)-61.23%
Year-to-Date Return-18.85%
5-Day Price Return-4.41%
EPS Normalized (Annual)$-0.65
ROA (5Y Avg)-34.95%
Net Profit Margin (Annual)-1764.51%
Month-to-Date Return23.11%
Cash Flow / Share (TTM)$-0.83
EBITD / Share (Annual)$-0.68
Operating Margin (Annual)-1937.85%
LT Debt / Equity (Annual)2.51x
ROI (5Y Avg)-49.81%
LT Debt / Equity (Quarterly)3.49x
EPS Basic Excl Extra (TTM)$-0.64
P/TBV (Quarterly)18.20x
P/B Ratio (Annual)18.20x
Pretax Margin (TTM)-1103.12%
Book Value / Share (Annual)$0.12
Price vs S&P 500 (13W)-16.54%
Beta1.11x
P/FCF (Annual)0.64x
Revenue / Share (TTM)$0.06
ROE (TTM)-658.91%
52-Week Low$1.03
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
IPHAInnate Pharma S.A. ADS | 28.95x | -64.68% | 0.81% | — | $1.59 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Innate Pharma is a clinical-stage biotechnology company developing cancer immunotherapies using its proprietary ANKET platform and therapeutic antibodies to engage the innate immune system. The company generates revenue through research collaborations and licensing agreements with pharmaceutical partners. Its pipeline includes lacutamab, monalizumab, and several other advanced immunotherapy candidates.